Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
editorial
. 1991 Jul;117(4):275–289. doi: 10.1007/BF01630709

The scientific bases of cancer management: at the interface between fundamental research and clinical practice

M Tubiana 1
PMCID: PMC12201899  PMID: 2066348

Abstract

From 1950 to 1985 the 5-year survival rate of cancer patients in industrialized countries, has slowly increased from 25% in 1950 to 50% in 1985. This progress has been due to earlier diagnosis and to a gradual improvement of treatment modalities. Clinical needs have stimulated basic research and clinical investigation. In turn, biological research has introduced new concepts and new agents. Clinical investigation and applied research have brought about an improvement in therapeutic methods and a better understanding of the growth and progression of human cancers which has, in particular, led to the concept of adjuvant treatment of occult metastases. The major recent breakthroughs in fundamental research have reinforced the value of close cooperation between clinicians and fundamentalists. Most of the new biologic tools are specific and only active on tumors cells with well-defined characteristics. Furthermore some new techniques such as adoptive immunotherapy can induce complete tumor regression in some patients and have no detectable effects in other patients with apparently similar tumors. Some cytokines have different effects on experimental and human tumors. The cytokine network is so complex that the administration of one of them can induce unpredictable effects. It has been recognized that experimental tumors and in vitro studies can be misleading and there is no substitute for clinical studies on patients. Moreover clinical experience has documented the amazing ability of tumors to become resistant to all these new agents. Numerous new therapeutic methods are being explored, however with the current state of knowledge it appears that although they can help to control tumors, they still fail to eradicate them. We must therefore learn how to integrate them with conventional therapies. Advances in therapy shall be achieved only by well-designed clinical trials. Thus at the interface between fundamental research and clinical practice there is an urgent need for oncologists with a strong scientific background and laboratory scientists with a deep interest in clinical investigations.

Abbreviations

MOPP

mechlorethamine, vincrestine, procarbazine, prednimurtine

ABVD

Adrianycin, bleomycin, vinblastine, dacarbazine

CEA

carcinoembryonic antigen

CT

chemotherapy

RT

radiotherapy

EGFr

epidermal growth factor receptor

ER, PR

estrogen and progesterone receptors

CSF

colony-stimulating factor

Footnotes

The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the author The Editors

Harold Dorn Memorial Lecture held at the closing ceremony of the International Congress of Cancer, Hamburg, August 1990

References

  1. Arbuck SG, Silk Y, Douglass HO, Nava H, Rustum YM, Milliron S (1990) A phase II trial of 5-fluoro-uracil, doxorubicin, mitomycin C., and leucovorin in advanced gastric carcinoma. Cancer 65:2442–2445 [DOI] [PubMed] [Google Scholar]
  2. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC, Klinjn JG, Visser TJ, Docter R, Lamberts SW (1990) Receptor scintigraphy with a radioiodinated somatostatin analogue. J NuclMed 31:1501–1509 [PubMed] [Google Scholar]
  3. Ball ED, Mills LE, Cornwell GG, Davis BH, Coughlin CT, Howell AL, Stukelt A, Dain BJ, McMillan R, Spruce W, Miller WE, Thompson L (1990) Autologous bone marrow transplantation of acute myeloid leukemia using monoclonal antibody purged bone marrow. Blood 75:1199–1206 [PubMed] [Google Scholar]
  4. Barth RF, Soloway AH, Fairchild RG (1990) Boron neutron capture therapy of cancer. Cancer Res 50:1061–1070 [PubMed] [Google Scholar]
  5. Berdel WE, Danhauser-Riedl S, Steinhauser G, Winton EF (1989) Various hematopoietic growth factors stimulate clonal growth of non hematopoitic tumor cells. Blood 73:80–83 [PubMed] [Google Scholar]
  6. Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B (1990) Incidence of response and long term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa — 2a. Blood 75:839–845 [PubMed] [Google Scholar]
  7. Bernstein ID, Eary JF, Badger CC, Press OW, Apfelbaum FR, Martin PJ, Krohn KA, Nelp WB, Porter B, Fisher S, Miller R, Brown S, Levy R, Thomas ED (1990) High dose radiolabeled antibody therapy of lymphoma. Cancer Res 50:1017S-1021S [PubMed] [Google Scholar]
  8. Borden EC, Sondel PM (1990) Lymphokines and cytokines as cancer treatment — immunotherapy realized. Cancer 65:800–814 [DOI] [PubMed] [Google Scholar]
  9. Brady LW, Markoe AM, Micaily B, Fisher SA, Lamm F (1990) Innovatives techniques in radiation oncology. Cancer 65:610–624 [DOI] [PubMed] [Google Scholar]
  10. Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM (1960) The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121–125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Buchegger F, Pelegrin A, Delaloye B, Bischof-Delaloye A, Mach JP (1990) Iodine-131-labeled MAb F(ab′)2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radio immunotherapy of large human colon carcinoma grafted in nude mice J Nucl Med 31:1035–1044 [PubMed] [Google Scholar]
  12. Butturini A, Keating A, Goldman J, Gale RP (1990) Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet 335:1255–1258 [DOI] [PubMed] [Google Scholar]
  13. Carbone PP (1990) Progress in the systemic treatment of cancer. Cancer 65:625–633 [DOI] [PubMed] [Google Scholar]
  14. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L (1990) All transretinoic acid as a differentiation therapy for acute promyelocytic leukemia — clinical results. Blood (in press) [PubMed]
  15. Chang J, Morgenstern GR, Coutinho LH, Scarff JH, Carr T, Deakin DR, Testa NG, Dexter TM (1989) The role of bone marrow cells grown in long term culture for autologous bone marrow transplantation in acute myeloid leukemia. Bone Marrow Transplant 4:5–9 [PubMed] [Google Scholar]
  16. Charbit A, Malaise EP, Tubiana M (1971) Relation between the pathological nature and the growth rate of human tumors. Eur J Cancer 7:307–315 [DOI] [PubMed] [Google Scholar]
  17. Demetri GD, Griffin JD (1990) Hematopoietic growth factors and high dose chemotherapy — will grams succeed where milligrams failed. J Clin Oncol 8:761–764 [DOI] [PubMed] [Google Scholar]
  18. De Nardo G, De Nardo S, O'Grady LF, Levy NB, Adams GP, Mills SL (1990) Fractionated radio-immunotherapy of B — cell malignancies with 131-1-lymph. Cancer Res 50:1014S-1016S [PubMed] [Google Scholar]
  19. De Vita VT (1983) Progress in cancer management. Cancer 51:2401–2409 [DOI] [PubMed] [Google Scholar]
  20. De Vita VT 1990 The problem of resistance. Keynote address. In: Mihich E (ed) Drug resistance: mechanism and reversal. Libbey, Roma, pp7–27 [Google Scholar]
  21. Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, Cummings G, Al Sarraf M (1984) Correlation between response to cis-Pt combination and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54:811–814 [DOI] [PubMed] [Google Scholar]
  22. Fantini J, Guo XJ, Marvaldi J, Rougeon G (1990) Suramin inhibits proliferation of rat glioma cells and alters N-cam cell surface expression. Int J Cancer 45:554–561 [DOI] [PubMed] [Google Scholar]
  23. Fertil B, Malaise EP (1981) Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol 7:621–629 [DOI] [PubMed] [Google Scholar]
  24. Foon KA (1989) Biological response modifiers — the new immunotherapy. Cancer Res 49:1621–1639 [PubMed] [Google Scholar]
  25. Frindel E, Monpezat JP (1989) The physiological role of the endogenous colony forming units-spleen (CFU-s) inhibitor — acetyl-N-Ser-Asp-Lys-Pro. Leukemia 3:753–754 [PubMed] [Google Scholar]
  26. Frindel E, Malaise E, Alpen EL, Tubiana M (1967) Kinetics of cell proliferation of an experimental tumor. Cancer Res 27:1122–1131 [PubMed] [Google Scholar]
  27. Gerharz CD, Gabberth HE, Engers R, Ramp U, Mayer H, Biesalki HK, Luley C (1989) Heterogeneous response to differentiationinduction in different clonal subpopulations of a rat rhabdomyosarcoma cell line. Cancer Res 49:7132–7140 [PubMed] [Google Scholar]
  28. Gianni AM, Bregni M, Siena S, Orazi A, Stern AC, Gandola L, Bonadonna G (1990) Recombinant human granulocyte-macrophage colony stimulating factor reduces hematologic toxicity and widens clinical applicability of high dose cyclophosphamide treatment in breast cancer and non-Hodgkin lymphoma. J Clin Oncol 8:768–778 [DOI] [PubMed] [Google Scholar]
  29. Goldie JH, Goldman AJ (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44:3643–3663 [PubMed] [Google Scholar]
  30. Griswold DP, Simpson-Herren L, Schabel FM (1970) Altered sensitivity of a hamster plasmocytoma to cytosine-arabinoside. Cancer Chem Rep 54:337–346 [PubMed] [Google Scholar]
  31. Guerin M, Barrois M, Terrier MJ, Spielmann M, Riou G (1988) Overexpression of either c-myc or c-erb B2 — new proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res 3:21–31 [PubMed] [Google Scholar]
  32. Guerin M, Gabillot M, Mathier MC, Travagli JP, Riou G (1989) c-Erb-B2 and EGF receptor genes in inflammatory and non-inflammatory breast cancers — association with cancers of poor prognosis. Cancer cells: 7:405–408 [Google Scholar]
  33. Guerin M, Sheng ZM, Andrieu N, Riou G (1990) Strong association between c-myb and oestrogen receptor expressionin human breast cancer. Oncogene 5:131–135 [PubMed] [Google Scholar]
  34. Hertler AA, Frankel AE (1989) Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol 7:1932–1942 [DOI] [PubMed] [Google Scholar]
  35. Howell AL, Stukel TA, Bloomfield CD, Davey FR, Ball ED (1990) Induction of differentiation in blast cells and leukemia colonyforming cells from patients whith acute myeloid leukemia. Blood 75:721–729 [PubMed] [Google Scholar]
  36. Huang M Ye HC, Chen SR, Lu HX, Zhoa L, Gu LJ, Wang ZY (1988) Use of all-trans retinoic acid in the treatment of acute promyelocitic leukemia. Blood 72:567–572 [PubMed] [Google Scholar]
  37. Kasid U, Pfeifer A, Brennan T, Beckett M, Weichselbaum RR, Dritschilo A, Mark GE (1989) Effect of antisense c-raf-I on tumorogenicity and radiosensitivity of a human squamous carcinoma. Science 243:1354–1356 [DOI] [PubMed] [Google Scholar]
  38. Kievit J, Van De Velde CJH (1990) Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up. Evaluation Cancer 65:2580–2587 [DOI] [PubMed] [Google Scholar]
  39. Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Shelps R, Franco S, Longo DL, Bann PA, Ihde DC (1990) Phase II trial of intermittent high dose recombinant Alfa 2 A interferon in mycosis fungoides and Sezary syndrome. J Clin Oncol 8:155–160 [DOI] [PubMed] [Google Scholar]
  40. Koscielny S, Tubiana M, Le MG, Valleron AJ, Mouriesse H, Contesso G, Sarrazin D (1984) Breast cancer — relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 59:775–782 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Koscielny S, Tubiana M, Valleron AJ (1985) A simulation model of the natural history of human breast cancer. Br J Cancer 52:515–524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Koscielny S, Le MG, Tubiana M (1989) The natural history of human breast cancer — the relationship between involvement of axillary lymph nodes and the initiation of distant metastases. Br J Cancer 59:775–782 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Krigel RL, Padavic-Shaler KA, Rudolph AR, Konrad M, Bradley EC, Comis RC (1990) Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta interferon. J Clin Oncol 8:460–467 [DOI] [PubMed] [Google Scholar]
  44. Lacour J, Lacour F, Ducot B, Spira A, Michelson M, Petit JY, Sarrazin D, Contesso G (1988) Poly-adenylic polyuridilic acid as an adjuvant in the treatment operable breast cancer: recent results. Eur J Surgical Oncol 14:311–316 [PubMed] [Google Scholar]
  45. Laurie JA, Moertel CG, Fleming TR, Wiehand HS, Leigh JE, Rubin T, McCormack GW, Gerstner JB, Krook JE, Malliard J, Twito DI, Morton RF, Tschetter LK, Barlow JF (1989) Surgical adjuvant therapy of large bowel carcinoma — an evaluation of levamisole and the combination of levamisole und fluoro-uracil. J Clin Oncol 7:1447–1456 [DOI] [PubMed] [Google Scholar]
  46. Le Chevalier T, Arriagada R, De The H, De Cremoux H, Martin M, Baldeyrou P, Ruffie P, Benna F, Carrina ML, Sancho-Garnier H, Hayat M (1988) Combination of chemotherapy and radiotherapy in limited small cell lung carcinoma — results of alternating schedule in 109 patients. Natl Cancer Inst Monogr 5:335–338 [PubMed] [Google Scholar]
  47. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin S (1990) A phase II trial of taxol in metastatic melanoma. Cancer 65:2478–2481 [DOI] [PubMed] [Google Scholar]
  48. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E (1989) Sequence determination of an inhibitor of hematopoietic pluripotent stem cell proliferation. Proc Natl. Acad Sci USA 86:779–782 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Mach JP, Buchegger F, Pelegrin A, Bischof-Delaloye A, Delaloye B (1990) Progress in radio-labeled monoclonal antibodies for cancer diagnosis and potential for therapy. In: Fortner JG, Rhoads JE (eds) Accomplishments in cancer research 1989 Lippincott, Philadelphia (in press) [Google Scholar]
  50. McKenna WG, Weiss Mc, Endlich B, Ling CC, Bakanauskas VS, Kelsten ML, Muschel RS (1990) Synergistic effect of the V-myc oncogene with H-ras on radioresistance. Cancer Res 50:97–1020 [PubMed] [Google Scholar]
  51. Malaise E, Tubiana M (1966) Croissance des cellules d'un fibrosarcome irradié chez la souris C3H. C R Acad, Sci [III] 263, 292–295 [PubMed] [Google Scholar]
  52. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmont F, Petrucci MT, Tribalto M, Vegna ML, Damacco F, Pileri A (1990) Maintenance treatment with recombinant interferon alfa 2 T in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430–1434 [DOI] [PubMed] [Google Scholar]
  53. Masui H, Kamrath H, Apell G, Houston LL, Mendelsohn J (1989) Cytotoxicity against human tumor cells mediated by the conjugate of anti epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res 49:3482–3488 [PubMed] [Google Scholar]
  54. Metcalf DE (1990) The colony stimulating factors. Cancer 65:2185–2195 [DOI] [PubMed] [Google Scholar]
  55. Meyer JS (1989) Measurements of cellular proliferation and DNA in breast carcinoma. In: Ragaz, Ariel (eds) High risk breast cancer. Springer, Berlin Heidelberg New York, pp 141–171 [Google Scholar]
  56. Meyer JS, Prey MU, Balook DS, McDivitt RW (1986) Breast carcinoma: cell kinetics, morphology, stage and host characteristics Lab Invest 54:41–51 [PubMed] [Google Scholar]
  57. Meyskens FL (1990) Coming of age — the chemoprevention of cancer N Engl J Med 323:825–827 [DOI] [PubMed] [Google Scholar]
  58. Mitchell MS, Harel W, Kempof RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L (1990) Active specific immunotherapy for melanoma. J Clin Oncol 8:856–869 [DOI] [PubMed] [Google Scholar]
  59. Mizel SB (1989) The interleukins. FASEBJ 3:2379–2388 [DOI] [PubMed] [Google Scholar]
  60. Moertel CG, Fleming TR, McDonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DG, Glick JH, Veeder MH, Maillard JA (1990) Levamisole and fluo-uracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358 [DOI] [PubMed] [Google Scholar]
  61. Order SE, Sleeper AM, Stillwagon GB, Klein JL, Leichner PK (1990) Radiolabeled antibodies — results and potential in cancer therapy. Cancer Res 50:1001S-1013S [PubMed] [Google Scholar]
  62. Parker BA, Vassos AB, Halpern SE, Miller RA, Hupf H, Amox DG, Simoni JI, Starr RJ, Green MR, Royston I (1990) Radio immunotherapy of human B-cell lymphoma with Y90 conjugated anti idiotype mono-clonal antibody. Cancer Res 50:1022S-1028S [PubMed] [Google Scholar]
  63. Peters LJ (1990) Inherent sensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiothe Oncol 17:177–190 [DOI] [PubMed] [Google Scholar]
  64. Piantadosi S (1990) Hazards of small clinical trials. J Clin Oncol 8:1–3 [DOI] [PubMed] [Google Scholar]
  65. Pradelles P, Frobert Y, Greminon C, Liozon E, Masse A, Frindel E (1990) Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun 170:986–993 [DOI] [PubMed] [Google Scholar]
  66. Price C Rohatiner A, Steward W, Wright J, Norton A, Deakin D, Bailey N, Blackledge G, Crowther D, Lister TA (1990) Interferon alfa as initial therapy in combination with chlorambucil in follicular lymphoma (abstract 55). Fourth International Conference on Malignant Lymphoma, Lugano, p 46
  67. Ravaud A, Eg Hbali H, Trojani M, Hoerni-Simon G, Souleyman P, Hoerni B (1990) Adjuvant BCG therapy in nonhodgkin's lymphoma. Long term results of a randomized trial in a single institution. J Clin Oncol 8:608–614 [DOI] [PubMed] [Google Scholar]
  68. Rio MC, Bellocq JP, Gairard B, Rasmusser UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R, Chambon P (1987) Specific expression of the pS2 gene in subclasses of breast cancers in comparison with the expression of the estrogene and progesterone receptors and the oncogeneerb-B2. Proc Natl Acad Sci USA 84:9243–9247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Rosenberg SA, Lotze MT, Yang JC, Linchan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DA (1989a) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863–1874 [DOI] [PubMed] [Google Scholar]
  70. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linchan WM, Seipp C, White DA (1989b) Experience with the use of high dose interleukin-2 in the treatment of 652 patients. Ann Surg 210:474–485 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Calver K, Miller AD, Blaese RM, Anderson WF (1990) Gene transfer into humans — immunotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570–578 [DOI] [PubMed] [Google Scholar]
  72. Sachs L (1990) The control of growth and differentiation in normal and leukemic blood cells. Cancer 65:2196–2206 [DOI] [PubMed] [Google Scholar]
  73. Samuels BL, Ultmann JE (1990) The detection of minimal disease and implications for cure initial. In: Ponder BAJ, Waring MJ (eds). The science of cancer treatment. Kluwer, Dordrecht, pp83–101 [Google Scholar]
  74. Saunders MI, Dische S, Hong A, Grosch EJ, Fermont DC, Ashford RF, Maher EJ (1989) Continuous hyperfractionated accelerated radiotherapy in locally advanced carcinoma of the head and neck region. Int J Radiat Oncol 17:1287–1293 [DOI] [PubMed] [Google Scholar]
  75. Schally AV (1988) Oncological applications of somatostatin analogues. Cancer Res 48:6977–6985 [PubMed] [Google Scholar]
  76. Schlimok G, Funke I, Bock B, Schweiberer B, Wible J, Riethmuller G (1990) Epithelial tumor cells in bone marrow of patients with colo rectal cancer: immuno-cyto-chemical detection, phenotypic characterization and prognostic significance. J Clin Oncol 8:831–837 [DOI] [PubMed] [Google Scholar]
  77. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso I, Caillou B, Permentier C (1986) Long term results of treatment of 283 patients with lung and bone metastases from thyroid cancer J Clin Endocrinol 63:960–967 [DOI] [PubMed] [Google Scholar]
  78. Siegel JA, Pawlik DA, Lee RE, Sasso NL, Horowitz JA, Sharkey RM, Goldenberg DM (1990) Tumor, red marrow and organ dosimetry for bilabeled anti-carcino-embryonic antigen monoclonal antibody. Cancer Res 50:1039S-1042S [PubMed] [Google Scholar]
  79. Stein CA, La Rocca RV, Thomas R, McAtee N, Myers CE (1989) Suramin: an anticancer drug with an unique mecanism of action. J Clin Oncol 7:499–508 [DOI] [PubMed] [Google Scholar]
  80. Steis RG, Sausville EA, Vach SR, Stocker JL, Sheps R, Frenco S, Longo DL, Bonn PA, Ihde DC (1990) Phase II trial of intermittent high dose recombinant alfa 2 a in mycosis fungoides and sezary syndrome. J Clin Oncol 8:155–160 [DOI] [PubMed] [Google Scholar]
  81. Tubiana M (1982) Cells kinetics and radiation oncology. Int J Radiat Oncol 8:1471–1489 [DOI] [PubMed] [Google Scholar]
  82. Tubiana M (1986) The growth and progression of human tumors. Implication for management strategy. Radiother Oncol 6:167–184 [DOI] [PubMed] [Google Scholar]
  83. Tubiana M (1989a) The role of radiotherapy in the treatment of chemosensitive tumors. Int J Radiat Oncol 16:763–774 [DOI] [PubMed] [Google Scholar]
  84. Tubiana M (1989b) Tumor cell proliferation kinetics and tumor growth rate Acta Oncol 28:111–121 [DOI] [PubMed] [Google Scholar]
  85. Tubiana M, Courdi A (1989) Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long term survival. Radiother Oncol 15:1–18 [DOI] [PubMed] [Google Scholar]
  86. Tubiana M, Frindel F, Malaise E (1968) The application of radiologic knowledge and cellular kinetics to radiation therapy. Am J Roentgenol 102:822–830 [PubMed] [Google Scholar]
  87. Tubiana M, Arriagada R, Cosset JM (1985a) Sequencing of drugs and radiations. The integrated alternating regimen. Cancer 55:2131–2139 [DOI] [PubMed] [Google Scholar]
  88. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C (1985b) Long term results and prognostic factors in patients with differentiated thyroid cancer. Cancer 55:794–804 [DOI] [PubMed] [Google Scholar]
  89. Tubiana M, Henry-Amar M, Carde P, Burgers JMV, Hayat M, Van Der Schueren E, Noordijk EM, Tanguy A, Meerwaldt JH, Thomas J, De Pauw B, Monconduit M, Cosset JM, Somers R (1989) Toward comprehensive management tailored to prognostic factors of patient with clinical stages and II in Hodgkin's disease. The EORTC lymphoma group controlled clinical trials 1964–1987. Blood 73:47–56 [PubMed] [Google Scholar]
  90. Tubiana M, Pejovic MH, Koscielny S, Chavaudra N, Malaise E (1989b) Growth rate, kinetics of tumor cell proliferation and long term outcome in human breast cancer. Int J Cancer 44:17–22 [DOI] [PubMed] [Google Scholar]
  91. Uckien FM, Souza L, Waddick KG, Wick M, Song CW (1990) In vivo radioprotective effects of recombinant human granulocyte CSF in lethally irradiated mice. Blood 75:638–645 [PubMed] [Google Scholar]
  92. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH (1989) Fluouracil and recombinant alfa-2a interferon: an active regimen against advanced colo rectal carcinoma. J Clin Oncol 7:1769–1775 Waldmann TA (1989) Multichain interleukin-2 receptor: a target for immunotherapy of lymphoma. J Natl Cancer Inst 81:914–9232585018 [Google Scholar]
  93. Weichselbaum RR, Beckett MA, Schwartz JL, Dritschilo A (1988) Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiat Oncol Biol Phys 15:575–579 [DOI] [PubMed] [Google Scholar]
  94. Youn JK, Kim BS, Min JS, Lee KS, Choi HJ, Lee YB, Lee DW, Park JS, Roh JK, Chung JB, Koh EH, Park YJ, Kim HI, Lee KB (1990) Adjuvant treatment of operable stomach cancer with polyadenilic poly uridylic acid in addition to chemotherapeutic agents. Int J Immunopharmacol 12:289–295 [DOI] [PubMed] [Google Scholar]
  95. Young RC (1990) Mechanisms to improve chemotherapy effectiveness. Cancer 65:815–822 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES